I did not get that negative feeling at all about pharma. It seemed to me her answer was almost in frustration in that it was always at the end of Phase2 that would maximise returns for shareholders in regards to partnerships.
Why on earth would they do one before all the data was collated. Of course you must have discussions and set the platform, which of course is what she is doing.
I read into that they were very happy with the health of patients and knew exactly which ones were responding and why.
If one wants to wait out P2, go ahead but you will paying dollars at that stage....AGN is already up 40% on 5 patients.
Ann: Phase 2 Stroke Clinical Trial Update, page-26
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
81.0¢ |
Change
0.035(4.52%) |
Mkt cap ! $100.1M | |||
| Open | High | Low | Value | Volume |
| 80.5¢ | 82.0¢ | 79.0¢ | $50.59K | 62.90K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9441 | 79.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 81.0¢ | 961 | 1 |
View Market Depth
| Last trade - 15.52pm 26/07/2024 (20 minute delay) ? |
| AGN (ASX) Chart |